Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 7/2018

01-07-2018 | Head and Neck

Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute

Authors: Ann-Jean C. C. Beck, Peter J. F. M. Lohuis, Abrahim Al-Mamgani, Laura A. Smit, Willem M. C. Klop

Published in: European Archives of Oto-Rhino-Laryngology | Issue 7/2018

Login to get access

Abstract

Purpose

The aggressive behavior of salivary duct carcinoma (SDC) necessitates an aggressive treatment strategy, including surgery and radiotherapy (RT). We evaluated practice patterns and treatment outcomes in patients with SDC treated in our Institute.

Methods

Patients with SDC of the parotid or submandibular gland treated with curative intention in our Institute from 1998 until 2016 were reviewed. Our diagnostic workup and treatment strategy were evaluated together with treatment outcomes.

Results

Fifteen patients with SDC were included. Staging included MRI and ultrasound-guided fine needle aspiration cytology. Only in a minority (20%) of patients, the preoperative diagnosis of SDC was raised due to positive immunohistochemical staining for the androgen receptor (AR) on cytology. All patients were treated with (sub)total resection of the salivary gland and 53% underwent a therapeutic neck dissection. All patients except one received postoperative RT. Immunohistochemical staining was found positive for AR (100%) and human epidermal growth factor receptor 2 (HER2/neu) (13%). No local recurrences occurred. Regional and distant failure rates were 20% and 40%, respectively.

Conclusions

Excellent local control rates can be achieved with extensive (local) surgical treatment and postoperative RT. In case of lymph node metastases, a neck dissection with adjuvant postoperative RT is warranted. In patients with node-negative disease, a less aggressive approach for the neck seems feasible to reduce treatment-related morbidity.
Literature
1.
2.
McHugh JB, Visscher DW, Barnes EL (2009) Update on selected salivary gland neoplasms. Arch Pathol Lab Med 133(11):1763–1774PubMed
3.
Jayaprakash V, Merzianu M, Warren GW, Arshad H, Hicks WL Jr, Rigual NR et al (2014) Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the surveillance, epidemiology, and end results database. Head Neck 36(5):694–701CrossRefPubMed
4.
Kleinsasser O, Klein HJ, Hubner G (1968) Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Archiv fur klinische und experimentelle Ohren- Nasen-Kehlkopfheilkunde 192(1):100–105CrossRef
5.
Seifert G, Brocheriou C, Cardesa A, Eveson JW (1990) WHO International histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract 186(5):555–581CrossRefPubMed
6.
Barnes L, Eveson J, Reichart P, Sidransky D (2005) World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. International Agency of Research on Cancer
7.
Johnston ML, Huang SH, Waldron JN, Atenafu EG, Chan K, Cummings BJ et al (2016) Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. Head Neck 38(Suppl 1):E820–E826CrossRefPubMed
8.
Borovec J, Cegan M, Mala K, Harmash N, Chramosta P, Kobierzycki C et al (2015) Histopathological case report of high grade salivary duct carcinoma. Folia Histochem Cytobiol 53(4):342–345CrossRefPubMed
9.
Otsuka K, Imanishi Y, Tada Y, Kawakita D, Kano S, Tsukahara K et al (2016) Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients. Ann Surg Oncol 23(6):2038–2045CrossRefPubMedPubMedCentral
10.
Hosal AS, Fan C, Barnes L, Myers EN (2003) Salivary duct carcinoma. Otolaryngol Head Neck Surg 129(6):720–725CrossRefPubMed
11.
Breinholt H, Elhakim MT, Godballe C, Andersen LJ, Primdahl H, Kristensen CA et al (2016) Salivary duct carcinoma: a Danish national study. J Oral Pathol Med 45(9):664–671CrossRefPubMed
12.
You HJ, Yun TK, Jeong SH, Dhong ES, Han SK (2016) Salivary duct carcinoma of the deep lobe of the parotid gland: a rare clinical finding. Arch Plastic Surg 43(1):107–110CrossRef
13.
Luk PP, Weston JD, Yu B, Selinger CI, Ekmejian R, Eviston TJ et al (2016) Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck 38(Suppl 1):E1838–E1847CrossRefPubMed
14.
15.
Skalova A, Starek I, Kučerová V, Szepe P, Plank L (2001) Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 197(9):621–626CrossRefPubMed
16.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRefPubMed
17.
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds) (2017) WHO classification of head and neck tumours, 4th edn. Lyon, IARC
18.
Stuiver MM, van Wilgen CP, de Boer EM, de Goede CJ, Koolstra M, van Opzeeland A et al (2008) Impact of shoulder complaints after neck dissection on shoulder disability and quality of life. Otolaryngol Head Neck Surg 139(1):32–39CrossRefPubMed
19.
Schmitt NC, Kang H, Sharma A (2017) Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol 74:40–48CrossRefPubMed
20.
D'heygere E, Meulemans J, Vander VP (2018) Salivary duct carcinoma. Curr Opin Otolaryngol Head Neck Surg 26(2):142–151CrossRefPubMed
21.
Nakano K, Sato Y, Sasaki T, Shimbashi W, Fukushima H, Yonekawa H et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Oto-laryngologica 136(9):948–951CrossRefPubMed
22.
Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24(17):2673–2678CrossRefPubMed
23.
Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF et al (2017) Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol 66:58–63CrossRefPubMed
24.
25.
Osborn V, Givi B, Lee A, Sheth N, Roden D, Schwartz D et al (2017) Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database. Oral Oncol 71:41–46CrossRefPubMed
26.
Mifsud M, Sharma S, Leon M, Padhya T, Otto K, Caudell J (2016) Salivary duct carcinoma of the parotid: outcomes with a contemporary multidisciplinary treatment approach. Otolaryngol Head Neck Surg 154(6):1041–1046CrossRefPubMed
27.
Gilbert MR, Sharma A, Schmitt NC, Johnson JT, Ferris RL, Duvvuri U et al (2016) A 20-year review of 75 cases of salivary duct carcinoma. JAMA Otolaryngol Head Neck Surg 142(5):489–495CrossRefPubMedPubMedCentral
28.
Nashed M, Casasola RJ (2009) Biological therapy of salivary duct carcinoma. J Laryngol Otol 123(2):250–252CrossRefPubMed
29.
Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J et al (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30(5):680–683CrossRefPubMed
30.
Kaidar-Person O, Billan S, Kuten A (2012) Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol (Northwood Lond Engl) 29(2):704–706CrossRef
31.
Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT et al (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29(16):e473–e476CrossRefPubMed
32.
Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A et al (2015) Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer (Oxford 1990) 51(3):271–281CrossRef
Metadata
Title
Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute
Authors
Ann-Jean C. C. Beck
Peter J. F. M. Lohuis
Abrahim Al-Mamgani
Laura A. Smit
Willem M. C. Klop
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 7/2018
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-018-5000-x

Other articles of this Issue 7/2018

European Archives of Oto-Rhino-Laryngology 7/2018 Go to the issue

Head and Neck

Frey Syndrome, First Bite Syndrome, great auricular nerve morbidity, and quality of life following parotidectomy

Head and Neck

Laser debulking or tracheotomy in airway management prior to total laryngectomy for T4a laryngeal cancer

Head and Neck

Microvessel density in head and neck squamous cell carcinoma

Short Communication

ENT audit and research in the era of trainee collaboratives

Laryngology

Provox 2® and Provox Vega® device life-time: a case-crossover study with multivariate analysis of possible influential factors and duration

Otology

Identification of dizzy patients who will develop an acute cerebrovascular syndrome: a descriptive study among emergency department patients